Jin Young Hwang

Jin Young Hwang

Auto-generated profile, based on publicly available information

Jin Young Hwang

Northwestern University Feinberg School of Medicine, Chicago, IL

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
JHJin-Young Hwang
Jin-Young Hwang
YKYu-Jin Kwon
Yu-Jin Kwon
WCWon-Jun Choi
Won-Jun Choi
DJDong Hyuk Jung
Dong Hyuk Jung

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
HYHyo-Sun You
Hyo-Sun You
JJJae-woo Jae-woo
Jae-woo Jae-woo
YKYe-Seul Kim
Ye-Seul Kim
Yonghwan KimYonghwan Kim
Yonghwan Kim
HLHyeongcheol Lee
Hyeongcheol Lee
Hee-Taik KangHee-Taik Kang
Hee-Taik Kang
You HS, et al. J Korean Med Sci. 2021 Mar;36(13):e82. https://doi.org/10.3346/jkms.2021.36.e82

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
WBWilliam Han Bae
William Han Bae
JHJin Young Hwang
Jin Young Hwang
WHWon Kyung Hur
Won Kyung Hur
JCJaeyoun Choi
Jaeyoun Choi
MNMyungwoo Nam
Myungwoo Nam
YCYoung Kwang Chae
Young Kwang Chae

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
WHWon Kyung Hur
Won Kyung Hur
JHJin Young Hwang
Jin Young Hwang
LKLeeseul Kim
Leeseul Kim
MNMyungwoo Nam
Myungwoo Nam
WBWilliam H. Bae
William H. Bae
YCYoung Kwang Chae
Young Kwang Chae
Background: Apart from its role in ovarian cancer progression, epithelial-mesenchymal transition (EMT) can promote chemotherapy resistance. We aimed to analyze how the EMT score would affect the tumor microenvironment in ovarian cancer. Methods: cBioportal was queried to obtain The Cancer Genome Atlas (TCGA) data for the serous ovarian cancer (SOC) cohort (TCGA, 585 patients). The neoantigen prediction data was derived from the CloudNeo pipeline using TCGA mutation calling. EMT scores were calculated by subtracting the average RNA-seq z-scores of three epithelial marker genes from the average RNA-seq z-scores of 13 mesenchymal marker genes as described in the previous study. Patient samples were grouped as either EMT-high (highest 1/3) or EMT-low (lowest 1/3). CIBERSORT was applied to predict the tumor-infiltrating immune cells. Results: Among the 585 SOC patients, only 256 patients had mutation data available for our analysis. The EMT-low group had a significantly higher mutation count (p value=0.0004) and cytolytic score (p value=0.032) than the EMT-high group. In addition, the EMT-low samples were associated with improved overall survival in SOC patients (HR, 0.55; 95% CI, 0.39-0.78; P < 0.001). The median survival of EMT-low was 57.40, and EMT-high was 41.06 months. Neoantigen counts and PD-L1 express level tended to be higher in the EMT-high group although failed to show statistical significance. The immune cell infiltration rates were not different between both groups. Conclusions: Our study is the first to describe the association between the EMT potential, neoantigen counts, and cytolytic scores in SOC. In our analyses, tumors with low EMT potential had a significantly higher neoantigen burden and higher cytolytic scores, suggesting that tumors with low EMT potentials tend to be more immunogenic. Further studies are warranted to explore the utility of EMT scores as biomarkers to predict the treatment response to immunotherapy in SOC. Citation Format: Won Kyung Hur, Jin Young Hwang, Leeseul Kim, Myungwoo Nam, William H. Bae, Yoonhee Choi, Yeun Ho Lee, Heayoon S. Cho, Emma Yu, Chan Mi Jung, William Cheng, Eugene Kim, Christmann Low, Victor Wang, Jeff Chuang, Young Kwang Chae. The neoantigen and immune landscape of epithelial mesenchymal transition (EMT) low and high score serous ovarian cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 626.

1 July 2021
Verified
Conference Paper
Closed access
WBWilliam H. Bae
William H. Bae
JHJin Young Hwang
Jin Young Hwang
WHWon Kyung Hur
Won Kyung Hur
MNMyungwoo Nam
Myungwoo Nam
YCYoon-hee Choi
Yoon-hee Choi
YCYoung Kwang Chae
Young Kwang Chae
TP53-mutation is a poor prognostic marker for uterine corpus endometrial carcinoma (UCEC). TGF-β is known to promote tumor progression via immune suppression, particularly NK and T cell-mediated cytotoxicity, in the tumor microenvironment. We aimed to analyze the impact of TGF-β signaling pathway-related gene mutation on the immune landscape and survival outcomes in TP53-mutated UCEC patients. cBioPortal was queried to obtain the UCEC The Cancer Genome Atlas cohort data (TCGA, 529 patients). The neoantigen counts were predicted using the CloudNeo pipeline. Survival outcomes were compared in the TGF-β signaling pathway-related gene mutated group, which were defined as genetic variances in TGFBR1, TGFBR2, ACVR2A, ACVR1B, SMAD2, SMAD3, or SMAD4, and the TGF-β signaling pathway-related gene non-mutated group. The cytolytic activity score was defined as a geometric mean of mRNA expression of perforin and granzyme. The duration of overall survival and disease-free survival were also obtained from cBioPortal. Out of the 529 UCEC patients, 192(36.3%) cancer tissues with TP53 mutations were analyzed for this study. 44 patients (22.9%) had more than one mutation in their TGF-β signaling pathway-related genes. TGF-β signaling pathway-related gene mutated group, when compared to a non-mutated group, was associated with significantly increased neoantigen counts (519.3 vs. 20.34 ; p<0.0001) and a significantly enhanced cytolytic activity (407.2 vs. 142.2; p<0.001). But there were no significant differences in PD-L1 expression level. The TGF-β pathway-related gene mutation was associated with improved disease-free survival (HR 0.29; 95% CI 0.13-0.67; p <0.05) and improved overall survival in TP53-mutated UCEC patients (HR, 0.32; 95% CI, 0.17-0.59; P < 0.001). In our analysis, TGF-β pathway-related gene mutations were correlated with significantly increased neoantigen count, higher cytolytic activity, and improved survival outcomes in TP53 mutated UCEC patients. Thus, TGF-β pathway-related gene mutations in TP53 mutated UCEC may be associated with increased cancer immunogenicity. Clinical treatment outcomes of UCEC with TGF-β pathway-related gene mutations should be explored in larger prospective studies. Citation Format: William H. Bae, Jin Young Hwang, Won Kyung Hur, Myungwoo Nam, Yoonhee Choi, Leeseul Kim, Yeun Ho Lee, William Cheng, Eugene Kim, Emma Yu, Chan Mi Jung, Jeff Chuang, Victor Wang, Young Kwang Chae. TGF-β signaling pathway-related gene mutations are associated with increased neoantigen counts, enhanced cytolytic activity, and improved survival outcomes in TP53-mutated endometrial carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 452.

1 July 2021 in Cancer Research
Verified
Journal Article
Closed access
WHWon Kyung Hur
Won Kyung Hur
JHJin Young Hwang
Jin Young Hwang
LKLeeseul Kim
Leeseul Kim
MNMyungwoo Nam
Myungwoo Nam
WBWilliam H. Bae
William H. Bae
YCYoung Kwang Chae
Young Kwang Chae
Background: Within serous ovarian cancer (SOC), high-grade serous carcinoma (HGSC) demonstrates a worse prognosis compared to low-grade serous carcinoma (LGSC). Molecular analysis of SOC has revealed a distinct pattern of mutations found between the two pathologic subtypes, with TP53 as the main driver for HGSC. We analyzed the neoantigen and immune landscape of different SOC subtypes according to pathological grades and mutation status. Methods: The analysis was done using the SOC cohort of The Cancer Genome Atlas (TCGA). The neoantigen prediction was done through the CloudNeo pipeline. CIBERSORT was applied to derive the tumor-infiltrating immune cells. Patients were grouped by their pathological grades (high vs. low) and the molecular features (type 1 vs. 2). For further subgroup analysis, high-grade samples were stratified by their TP53 mutation status. Results: Among 585 SOC patients, a subset of 254 patients with available mutation counts and predicted neoantigen counts were included. There was no significant difference in neoantigen count between low and high grades (median 50.50 vs. 62.50, p=0.84). However, there was a trend for differential numbers in the neoantigen count between type 1 and type 2 (median 29 vs. 66.50, p=0.07). No notable differences were detected in immune landscapes of low vs. high grade and type 1 vs. type 2. Conclusions: Our study is the first to describe the neoantigen and immune landscape of SOC. There were no significant differences in the immune landscape between the subtypes. It seems that molecular subtyping is more related to neoantigen differences than histologic subtyping. It is likely that the neoantigen differences are not defined by the histologic grade but rather by molecular trait. Citation Format: Won Kyung Hur, Jin Young Hwang, Leeseul Kim, Myungwoo Nam, William H. Bae, Yoonhee Choi, Yeun Ho Lee, William Cheng, Heayoon S. Cho, Emma Yu, Chan Mi Jung, Eugene Kim, Christmann Low, Victor Wang, Jeff Chuang, Young Kwang Chae. The neoantigen and immune landscape of low and high grade serous ovarian cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 453.